BIVI BIOVIE INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1580149 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY54.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-143.7%
ROA-119.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets40.9%
Debt / equity0.00x
Current ratio2.40x
Interest coverage-1,363.57x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-19.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.34M | $3.58M | $3.18M | $4.27M | $2.94M | $1.22M | $1.34M | $4.70M |
| SG&A expense | $2.31M | $2.13M | $2.15M | $1.94M | $2.29M | $2.38M | $1.59M | $2.53M |
| Operating income | -$5.65M | -$5.72M | -$5.39M | -$6.26M | -$5.28M | -$3.66M | -$2.99M | -$7.29M |
| Interest expense | $968 | $3,978 | $5,967 | $5,967 | $1,989 | $4,998 | $4,998 | $66,700 |
| Net income | -$5.61M | -$5.65M | -$5.27M | -$6.07M | -$5.09M | -$3.49M | -$2.79M | -$7.11M |
| EPS (basic) | -0.68 | — | -0.70 | -0.77 | -0.98 | — | -1.51 | -4.55 |
| EPS (diluted) | -0.68 | — | -0.70 | -0.77 | -0.98 | — | -1.51 | -4.55 |
| Weighted avg. shares (diluted) | 8.27M | — | 7.54M | 7.92M | 5.21M | — | 1.85M | 1.57M |
| Balance sheet | ||||||||
| Cash & equivalents | $7.73M | $8.98M | $13.10M | $20.54M | $24.98M | $17.54M | $23.15M | $24.41M |
| Current assets | $10.45M | $13.64M | $16.88M | $21.79M | $26.03M | $20.70M | $23.72M | $24.68M |
| Goodwill | $345,711 | $345,711 | $345,711 | $345,711 | $345,711 | $345,711 | $345,711 | $345,711 |
| Intangibles | — | — | $6,308 | $63,653 | $120,997 | $178,341 | $235,685 | $293,030 |
| Total assets | $11.04M | $14.25M | $17.51M | $22.50M | $26.82M | $21.56M | $24.66M | $25.69M |
| Current liabilities | $4.35M | $3.80M | $1.69M | $3.01M | $1.64M | $2.27M | $2.55M | $1.46M |
| Total liabilities | $4.51M | $3.98M | $1.91M | $3.24M | $1.90M | $2.55M | $2.84M | $1.77M |
| Shareholders' equity | $6.53M | $10.27M | $15.61M | $19.27M | $24.92M | $19.01M | $21.82M | $23.92M |
| Shares outstanding | 8.69M | 7.54M | 7.54M | 7.54M | 7.54M | 1.91M | 18.52M | 18.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.91M | -$4.12M | -$7.44M | -$4.44M | -$3.02M | -$5.61M | -$1.25M | -$8.58M |
| Financing cash flow | $1.66M | $0 | $0 | $0 | $10.46M | $0 | $0 | $12.97M |
| Stock-based compensation | $202,544 | $256,719 | $1.56M | $197,336 | $268,388 | $352,809 | $338,412 | $385,328 |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.